Does Shire's oncology sale mean Takeda may no longer be interested in making a takeover offer?
Rare diseases specialist Shire (SHP) has agreed to sell its oncology business for $2.4bn to French pharma company Servier, but investors may be curious if this impacts a potential takeover of Shire by Takeda which last month...
16 April 2018
